MOTS-c

MOTS-c is a mitochondrial-derived peptide that has been studied in preclinical and early translational research for potential impacts on metabolism, insulin sensitivity, and cellular stress responses.

It is not part of standard care for metabolic disease.

Experimental work suggests that MOTS-c can influence pathways related to AMPK activation, glucose utilization, and mitochondrial function.

These findings are largely derived from animal models and cell studies.

Interest in MOTS-c centers on metabolic and age-related conditions, but any potential therapeutic roles remain investigational.

Catalog listing reflects research and wellness discussions rather than guideline-based indications.

MOTS-c is written into the WADA Prohibited List by its full formal name. It sits in S4.4.1, under "Activators of the AMP-activated protein kinase (AMPK)," in the same bullet as BAM15 and AICAR. USADA confirms the classification directly: "Yes, MOTS-c is prohibited at all times under Section 4.4 Metabolic Modulators, 4.4.1. Activators of the AMP-activated protein kinase (AMPK) on the World Anti-Doping Agency Prohibited List," and notes that "it is explicitly listed as mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)" (USADA, "What is the MOTS-c peptide?").

Two details of the placement are worth reading carefully. First, MOTS-c is prohibited under S4, not S2 — but it is still a non-Specified Substance: the 2026 List states that substances in classes S4.3 and S4.4 are non-Specified, while only S4.1 and S4.2 are Specified. The reduced-sanction pathway available for some Specified Substances does not apply. Second, the prohibition is by mechanism. MOTS-c is caught because it activates AMPK, not because of its sequence, so analogues and modified versions marketed under other names are caught by the same bullet.

"It's an endogenous peptide" is not an argument. MOTS-c is encoded within mitochondrial DNA and circulates naturally, which makes the "it's already in your body" framing tempting. Testosterone is also endogenous and also prohibited. What anti-doping rules restrict is administration, and the analytical problem — distinguishing an injected peptide from the body's own — is one laboratories handle routinely for endogenous substances.

Detection. A validated method exists. Knoop and colleagues developed an LC/MS assay for MOTS-c in doping-control plasma samples, "fully validated for quantitative results interpretation according to the World Anti-Doping Agency's International Standard for Laboratories (WADA's ISL)," reaching "a lower limit of detection (LLOD) for hMOTS-c in plasma at 100 pg/mL." The assay also covers "four in vitro derived metabolites and two oxidation products, which might further improve the traceability of the drug" (Knoop et al., Rapid Commun Mass Spectrom 2019).

One caveat from that same paper deserves flagging honestly, because it is a live scientific question rather than a settled one: the authors could not reconcile their mass-spectrometric measurements with commercial ELISA results, reporting that "endogenous levels of a reference population of 20 healthy subjects studied by ELISA experiments (45.9-218.5 ng/mL) could not be confirmed by LC/MS." Setting a reference range for an endogenous peptide is exactly the step that determines where a decision limit sits, and that work is not finished. It is a reason the detection landscape may change, not a reason to treat the substance as permitted.

USADA also warns about what is actually in gray-market vials, listing reported effects among people who bought MOTS-c online — "increased heart rate or heart palpitations, injection site irritation, insomnia, local or generalized immune reactions, and fever" — and stating flatly that "there is no data available on what happens with long-term use of MOTS-c."

Long-term effects of directly modulating mitochondrial pathways in humans are not fully understood.

MOTS-c is an exercise-mimetic peptide. It is known for causing injection site pain.

This information summarizes commonly discussed research practices.

MOTS-c is supplied as a lyophilized powder for reconstitution and subcutaneous injection. The one formulation question with a documented answer comes from the registered phase 2a protocol, which uses subcutaneous administration once daily for 12 weeks (NCT07505745) — a schedule that differs substantially from the intermittent patterns described in community material.

Studies have explored MOTS-c in metabolic syndrome models, aging-related pathways, and exercise physiology, focusing on surrogate markers more than long-term clinical outcomes.

For deeper dives on this peptide, see:

• MOTS-c benefits and areas of interest
• MOTS-c side effects and safety context
• MOTS-c dosing concepts (educational)
• MOTS-c research and evidence overview

Has anyone been given MOTS-c in a study? Not in any published one. The frequently cited human papers measured endogenous levels: a randomized exercise study in 30 people (PMID 34351816) and an intralipid-plus-insulin infusion study in women with PCOS and controls (PMID 31066084). Participants received exercise or a lipid infusion, not the peptide. The first interventional trial — phase 2a, 120 adults with prediabetes, subcutaneous MOTS-c once daily for 12 weeks (NCT07505745) — is recruiting and has posted no results.

Does MOTS-c rise with exercise? Less reliably than usually claimed. In that 30-person randomized study, circulating humanin rose significantly after endurance exercise while MOTS-c showed only a trend, and resistance exercise moved neither. Neither peptide correlated with VO2max, leg strength, or muscle mitochondrial DNA copy number.

Is the AMPK mechanism real? Yes, and it is more specific than most peptide mechanism claims. The 2015 Cell Metabolism discovery paper (PMID 25738459) identified a 16-amino-acid peptide encoded in mitochondrial DNA that inhibits the folate cycle and de novo purine biosynthesis, activating AMPK, with skeletal muscle as its apparent primary target.

Did it work in animals? Yes. In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance and prevented diet-induced obesity. A 2018 follow-up showed it translocating to the nucleus under metabolic stress to regulate gene expression (PMID 29983246). Mouse metabolic rescue is a reason to run a human trial, not a substitute for one.

Is MOTS-c approved? No. It is not an FDA-approved drug and is not authorized as a treatment for any condition in any major jurisdiction.